《AbbVie JP Morgan 2022_Final.pdf》由会员分享，可在线阅读，更多相关《AbbVie JP Morgan 2022_Final.pdf（21页珍藏版）》请在三个皮匠报告上搜索。

1、J.P.Morgan Healthcare Conference|January 11,20221J.P.Morgan Healthcare Conference Rob MichaelVice Chairman,Finance and Commercial OperationsChief Financial OfficerJanuary 11,2022J.P.Morgan Healthcare Conference|January 11,20222Forward-Looking Statements and Non-GAAP Financial informationSome stateme

2、nts in this presentation are,or may be considered,forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.The words“believe,”“expect,”“anticipate,”“project”and similar expressions,among others,generally identify forward-looking statements.AbbVie cautions that

3、these forward-looking statements are subject to risks and uncertainties,including the impact of the COVID-19 pandemic on AbbVies operations,results and financial results,that may cause actual results to differ materially from those indicated in the forward-looking statements.Such risks and uncertain

4、ties include,but are not limited to,failure to realize the expected benefits of the Allergan acquisition,failure to effectively integrate Allergans businesses,challenges to intellectual property,competition from other products,difficulties inherent in the research and development process,adverse lit

5、igation or government action,and changes to laws and regulations applicable to our industry.Additional information about the economic,competitive,governmental,technological and other factors that may affect AbbVies operations is set forth in Item 1A,“Risk Factors,”of AbbVies 2020 Annual Report on Fo

6、rm 10-K,which has been filed with the Securities and Exchange Commission,as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update,supplement or supersede such information.AbbVie undertakes no obliga

7、tion to release publicly any revisions to forward-looking statements as a result of subsequent events or developments,except as required by law.This presentation contains GAAP and certain non-GAAP financial measures.Non-GAAP financial measures are adjusted for certain non-cash items and for factors

8、that are unusual or unpredictable,and exclude those costs,expenses and other specified items presented in AbbVies reconciliation tables.AbbVies management believes non-GAAP financial measures provide useful information to investorsregarding AbbVies results of operations and assist management,analyst

9、s and investors in evaluating the performance of the business.Non-GAAP financial measures should be considered in addition to,and not as a substitute for,measures of financial performance prepared in accordance with GAAP.Reconciliations of these non-GAAP financial measures to the most comparable GAA

10、P measures are available in the appendix to this presentation and on the companys website at .Todays discussions and presentation are intended for the investor community only;materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions.

11、J.P.Morgan Healthcare Conference|January 11,20223Not for promotional useAbbVie is a Diversified Biopharmaceutical Company with Multiple Sources of Growth and Strong Long-term OutlookImmunologyHematologicOncologyNeuroscienceAestheticsBest-in-Class medicines position AbbVie for sustained leadership;Si

12、gnificant growth potential for new assetsStrong leadership position;Building a broad pipeline across a range of blood cancers for sustainable long-term growth Positioned for significant growth with attractive commercial opportunities across Migraine,Psychiatry Neuro-DegenerationLeadership positions

13、across core Aesthetics areas;New products,global expansion and increasing penetration expected to drive significant long-term growthFollowing U.S.Humira LOE in 2023,expect modest top-line growth in 2024 and return to strong top-line growth in 2025,with high-single digit CAGR through remainder of dec

14、ade Eye CareLarge franchise with investment opportunities to sustain eye care leadership and drive growth with internal and external innovationJ.P.Morgan Healthcare Conference|January 11,20224Not for promotional use Strong operating cash flow to support investments for growth,return of cash to share

15、holders and rapid debt repayment Continued R&D investment in promising,innovative science across each of our therapeutic categories,as well as capacity to pursue additional mid-to late-stage pipeline assets to augment the internal pipeline Committed to a robust and growing dividend;Increased quarter

16、ly dividend by 250%since inception A Unique Investment Opportunity Well Positioned For Continued Strong Shareholder ReturnsCompelling capital allocation philosophy,balanced between supporting growth and returning capital to shareholdersJ.P.Morgan Healthcare Conference|January 11,20225Not for promoti

17、onal useStrong Financial Execution Since Inceptionas an Independent Company$18.8$19.9$22.8$25.6$28.2$32.7$33.3$45.8$56.2*20001920202021Adjusted Net Revenues($in billions)$3.14$3.32$4.29$4.82$5.60$7.91$8.94$10.56$12.65*20001920202021Adjusted EPS14.7%CAGR19.

18、0%CAGR*Based on FY21 guidance provided on 3Q21 earnings call.AbbVie issued sales guidance of approximately$56.2B and adjusted EPS guidance of$12.63 to$12.67Met or exceeded both total revenue and adjusted EPS guidance in all 35 quarters since becoming an independent companyJ.P.Morgan Healthcare Confe

19、rence|January 11,20226Not for promotional useOn Track To Meet or Exceed Allergan Transaction Financial Commitments6Generate$2B in Synergies and Cost Savings in Year 3On-Track Expect$1.8B in expense synergies in 2021 On track to achieve$2B in 202210%Accretion Over the First Full Year of Combination,P

20、eaking at 20%Accretion meaningfully exceeded 10%in the first year following the Allergan acquisition On track to deliver 20%peak accretionOn-TrackReduce debt by$15B-$18B before end of 2021,with further deleveraging through 2023 Repaid$17B of combined company debt through the end of 2021 Expect to ac

21、hieve net leverage ratio of 2.0 x by the end of 2022On-TrackJ.P.Morgan Healthcare Conference|January 11,20227Not for promotional useImmunologyTransformed Immunology From a Single Product with Humira to a Portfolio Of Differentiated Therapies with the Addition of Skyrizi and Rinvoq$1.6B$2.9B$7.5B$0.7

22、B$1.7B$7.5B$0.4B$2.3B$4.6B$15B201920202021Guidance2025GuidanceSkyriziRinvoq$6.0B PsO+PsA$1.5B IBD$3.5B RA$1.7B AD$1.0B SpA$1.3B IBDExpect combined risk-adjusted global sales of$15 billion for Rinvoq and Skyrizi in 2025,with combined peak sales for Rinvoq and Skyrizi expected to exceed Humira peak re

23、venuesInternational markets expected to contribute sales of$4.5B for Skyrizi and Rinvoq based on strong labels in approved indications and outstanding launches across indications J.P.Morgan Healthcare Conference|January 11,20228Not for promotional useImmunologyPipeline of Novel Therapies to Improve

24、Clinical Performance Across Rheumatology,Dermatology and GastroenterologyABBV-154ABBV-157ABBV-668Novel approach to target immunomodulation without steroid adverse effectsDesigned to provide transformational efficacy in AbbVies core indicationsCurrently in Phase 2b dose-ranging study in RA and Phase

25、2 in CD,PMRPotential to more effectively inhibit IL-17 production than antagonist approachesPromising activity in Phase 1 study in psoriasis patientsPhase 2b dose-ranging study initiated Q4 2021Differentiated approach to modulating inflammation by inhibiting RIPK1 and inflammatory cytokine productio

26、nPotential to prevent necroptosis and reduce TLR4-driven inflammation to benefit patients with immune-mediated diseases(e.g.UC,CD,PsO)Expect to begin Phase 2 studies in 2022Anti-TNF Steroid Antibody Drug ConjugateSmall Molecule RoRg gT Inverse Agonist Small Molecule RIPK1 InhibitorJ.P.Morgan Healthc

27、are Conference|January 11,20229Not for promotional use 6 FDA Breakthrough Therapy designations and 4 approved indications across CLL and AML populations Nearing completion of registrational programs in MM and MDS Potential to become a foundational therapy in multiple hematologic malignancies,allowin

28、g patients to achieve more durable,deeper responses,including the option for some patients to stop treatment Gold standard in CLL and preferred treatment for MCL and WM Most comprehensive efficacy and safety data in the BTK inhibitor class,with six positive Phase 3 CLL studies demonstrating superior

29、ity over all standard-of-care chemotherapy-based regimens Unmatched body of data showing sustained disease control and survival benefit will enable Imbruvica to maintain a strong competitive positionOncologyEstablished a Strong Leadership Position in Hematologic Oncology with Imbruvica and Venclexta

30、J.P.Morgan Healthcare Conference|January 11,202210Not for promotional useOncologyBuilding a Broader,Deeper Pipeline to Address Significant Unmet Need in Oncology and Position Franchise for Sustainable Long-Term GrowthNavitoclaxEpcoritamabTeliso-VCurrent myelofibrosis therapies provide symptom relief

31、,with minimal impact on underlying course of the diseaseEncouraging Phase 2 data demonstrates potential for anti-fibrosis activity to deliver significant reductions in bone marrow fibrosis and durable clinical improvementsPivotal trial readouts,regulatory submission and approval anticipated in 2023E

32、ncouraging early clinical data demonstrate competitive ORR/CR in DLBCL and FL,with manageable safety profilePotential to be a best-in-class CD3-CD20 bispecific across B cell malignancies,e.g.DLBCL and FLPhase 3 ongoing in relapsed/refractory DLBCL and additional Phase 3 studies to begin in 2022;Phas

33、e 2 expansion cohorts ongoing in DLBCL and FL,with potential to support regulatory submission in 2H 2022Teliso-V granted Breakthrough Therapy Designation based on promising Phase 2 data in 2L+non-squamous NSCLC patients with wild-type EGFR and overexpressed c-Met(25%of non-sq.NSCLC population)Next-g

34、eneration c-Met ADC utilizing a topoisomerase inhibitor payload(ABBV-400)in Phase 1,with potential to provide deeper responses with broader applicabilityLonger-term Phase 2 Teliso-V data expected in 2023,with potential to support accelerated approvalBCL-2/BCL-xL InhibitorCD3-CD20 Bispecificc-Met ADC

35、ABBV-383Emerging clinical data demonstrate potential to provide best-in-class efficacy and safety across lines of therapy in MMExpect to begin Phase 3 studies in relapsed/refractory MM in 2022BCMA-CD3 BispecificJ.P.Morgan Healthcare Conference|January 11,202211Not for promotional useNeuroscienceBuil

36、ding a Leading Portfolio with Options for Every Patient Across the Migraine SpectrumAcute Migraine Treatment#1 prescribed branded acute treatment for migraine*Rapid share uptake and broad commercial access Expect$1B in peak salesEpisodic Migraine PreventionChronic Migraine Prevention Only oral CGRP

37、receptor antagonist specifically developed for the preventive treatment of migraine Strong efficacy data and favorable safety profile demonstrated in robust clinical development program Encouraging early launch trends and growing market access Potential expansion into chronic migraine prevention(Pha

38、se 3 ongoing)Expect$1B in peak sales Unique foundational treatment for prevention of chronic migraine Branded leader in new patient starts Potential expansion into episodic migraine(Phase 3 ongoing)*Based on IQVIA cumulative TRx data through 12/24/21J.P.Morgan Healthcare Conference|January 11,202212

39、Not for promotional useNeuroscienceSignificant Growth Opportunities in Psychiatry and Neuro-Degeneration A versatile atypical antipsychotic that provides strong efficacy across multiple symptoms,with minimal impact on weight,lipids and fasting blood glucose Expect Vraylar peak sales to approach$4B w

40、ith current approved indications (schizophrenia,bipolar I disorder,bipolar depression)Expect to submit regulatory application 1H 2022 as an adjunctive treatment of major depressive disorder which,if approved,would represent a significant opportunity for VraylarAdvancing A Transformative Pipeline For

41、 Parkinsons and Alzheimers Diseases ABBV-951:Nearing completion of registrational program for subcutaneous levodopa/carbidopa delivery system with approvals anticipated in early 2023;Potentially transformative improvement to current treatment options for patients with advanced Parkinsons disease.Exp

42、ect ABBV-951 to reach peak sales of$1B Early-Stage Programs in Alzheimers Disease:Focused on optimized a-beta antibody approaches for faster amyloid clearance with low ARIA and patient friendly dosing regimen,as well as clearing intracellular tau aggregates and modulating neuroinflammatory response

43、J.P.Morgan Healthcare Conference|January 11,202213Not for promotional useAestheticsMarket Leader in Global Aesthetics with Significant Growth Opportunities from New Product Introduction,Global Expansion and Increasing Market PenetrationIncreased Investments Driving Strong Growth Increased investment

44、s to retain existing patients,activate new consumers,train injectors and help our customers grow their practices Enhanced and more consistent promotional spending Enhanced digital products and services for patients and providers through All platform Expanding footprint and resources in major global

45、marketsAccelerating R&D Programs&Strengthening Pipeline with Business Development Innovative Toxins:Short-acting and long-acting toxins both in Phase 2 development Novel Dermal Fillers:Bio-stimulatory and regenerative fillers,HArmonyCa filler Body Contouring:Next-gen CoolSculpting,CoolTone,Soliton f

46、or celluliteAesthetics Franchise Positioned for Sustainable Long-term Growth Expect high-single digits revenue CAGR for Aesthetics business through 2029,substantially higher than previous expectations for mid-single digit growth at the time of the Allergan transaction announcement Expect Aesthetics

47、sales of$9B in 2029J.P.Morgan Healthcare Conference|January 11,202214Not for promotional useEye Care$3.5 billion Franchise with Investment Opportunities to Sustain Eye Care Leadership and Drive Growth with Internal and External InnovationMaximize Current Portfolio in Glaucoma and Dry Eye Multiple le

48、ading brands to help preserve and protect vision Highly profitable businesses that generate significant cash flow for future investmentDevelop Novel Products to Support Long-Term Growth Successfully launch Vuity,the first FDA-approved eye drop to treat presbyopia Establish a strong position in retin

49、al diseases with longer duration delivery technology such as RGX-314,a potential one-time gene therapy for wet AMD,diabetic retinopathy and other chronic retinal conditions Build a novel pipeline to address significant unmet needs in large,growing Eye Care marketsJ.P.Morgan Healthcare Conference|Jan

50、uary 11,202215Not for promotional useInnovation-Driven R&D OrganizationProven Track Record of Developing New Medicines That Consistently Elevate the Standard of Care185+ClinicalTrials5Core TherapeuticAreas11K+R&DEmployees$6.7BAnnual R&D Investment*$2.0BAnnual Business Development Allocation80+Clinic

51、alPrograms50New MolecularEntities40+ConditionsTreated21 Major Product or Indication Approvals*65+New Study StartsPlanned for 2022*Reflects approvals since 2013*Based on FY21 guidance provided on 2Q21 earnings call for non-GAAP R&D expense.J.P.Morgan Healthcare Conference|January 11,202216Not for pro

52、motional useAbbVie PipelineAs of January 11,2022Excludes devices in development*Partnered assets;See appendix for partnership summaryABBV-668(RIPK1)Multiple Immunology DiseasesABBV-151(GARP+TGFb1)Solid TumorsABBV-155(BCL-xL ADC)Solid TumorsABBV-400(cMet ADC)NSCLCABBV-181(PD-1)Solid TumorsABBV-621(TR

53、AIL)Solid/Heme TumorsABBV-744(BET)MFABBV-927(CD40)Solid TumorsABBV-647*(PTK7 ADC)NSCLCABBV-011(SEZ6 ADC)SCLCABBV-637(EGFR BCL-xL ADC)NSCLCVenclexta(BCL-2)ALLCCW702*(CD3-PSMA)Prostate CancerCLBR001/SWI019*(sCAR-T)Heme TumorsGEN3009*(CD37)Heme TumorsJAB-3068*/JAB-3312*(SHP2)Solid TumorsHPN-217*(CD3-BC

54、MA)MMABBV-383(CD3-BCMA)MMTTX-030*(CD39)Solid TumorsABBV-IMAB-TJC4*(CD47)Heme/Solid TumorsABBV-CLS-579*(PTPN2)Solid TumorsABBV-CLS-484*(PTPN2)Solid TumorsABBV-514(CCR8)Solid TumorsABBV-0805*(a-Synuclein)PDAL003*(CD33)ADABBV-CLS-7262*(elF2B)Multiple NeuroAGN-241622(Alpha2)PresbyopiaABBV-1882(anti-PD1/

55、anti-a4b7)HIVABBV-154(TNF-Steroid ADC)RAABBV-154(TNF-Steroid ADC)PMRABBV-154(TNF-Steroid ADC)CDABBV-599(BTK/JAK)SLEABBV-157(RORgT)PsORinvoq(JAK 1)VitiligoAcazicolcept ALPN-101*(ICOS/CD28)SLELutikizumab(IL-1a/1b)HSEpcoritamab*(CD3-CD20):R/R FLABBV-CX-2029*(CD71)Solid/Heme TumorsElezanumab(RGMa)Stroke

56、Elezanumab(RGMa)SCIAL002*(TREM2)ADBoNTE(SNARE)Glabellar LinesOnabotA X(SNARE)Glabellar LinesOnabotA X(SNARE)Forehead LinesAGN-231868(Chemokine)Dry EyeAGN-242428(RORg)Dry EyeRGX-314*(NAV AAV8 Anti-VEGF Fab)wAMD Suprachoroidal Delivery RGX-314*(NAV AAV8 Anti-VEGF Fab)DR Suprachoroidal DeliveryAGN-1934

57、08(Prostamide 408 SR)GlaucomaCF Triple Combo(CFTR-C1/CFTR-C2/CFTR-P)Armour Thyroid(T3T4)HypothyroidismAGN-151607(SNARE)Atrial FibrillationRinvoq(JAK 1)CDRinvoq(JAK 1)GCASkyrizi*(IL-23)UCImbruvica*(BTK)1L FLImbruvica*(BTK)1L MCLImbruvica*(BTK)+Venclexta(BCL-2)R/R MCLImbruvica*(BTK)R/R FL/MZLImbruvica

58、*(BTK)+Venclexta(BCL-2)1L CLLVenclexta*(BCL-2)AML MaintenanceVenclexta*(BCL-2)R/R MM t(11;14)Venclexta*(BCL-2):MDSNavitoclax(BCL-2/BCL-xL)MyelofibrosisEpcoritamab*(CD3-CD20):R/R DLBCLTeliso-V*(cMet ADC)NSCLCVeliparib(PARP)BRCA Breast CancerVeliparib(PARP)1L Ovarian CancerABBV-951(dopamine receptor)P

59、DVraylar*(D2,5-HT1A,5-HT2A)aMDDQulipta(CGRP)Chronic Migraine Prev.Botox(SNARE)Masseter ProminenceBotox(SNARE)Platysma ProminenceRGX-314*(NAV AAV8 Anti-VEGF Fab)wAMD Subretinal Delivery Aztreonam/Avibactam*(PBP3)InfectionRinvoq(JAK 1)AD(US)Rinvoq(JAK 1)AS(US)Rinvoq(JAK 1)UCRinvoq(JAK 1)nr-Axial SpASk

60、yrizi*(IL-23)PsA(US)Skyrizi*(IL-23)CDPhase 1Phase 2Registrational/Phase 3SubmittedImmunologyOncologyNeuroscienceAestheticsEye CareTargeted InvestmentJ.P.Morgan Healthcare Conference|January 11,202217Not for promotional useAnticipated Key Pipeline Events20222023RegulatoryApprovalsRinvoq AD(US)Rinvoq

61、AS(US)Rinvoq UCRinvoq nr-Axial SpASkyrizi CDSkyrizi PsA(US)Imbruvica+Venclexta 1L CLLVenclexta Higher Risk MDS(AA)Vraylar aMDDRinvoq CDImbruvica+Venclexta R/R MCLImbruvica R/R FL/MZLVenclexta 3L+MM w/t(11;14)Navitoclax 1L and R/R MFEpcoritamab 3L R/R DLBCL(AA)ABBV-951 Advanced PDQulipta Chronic Migr

62、aine Prevention RegulatorySubmissionsRinvoq CDImbruvica+Venclexta 1L CLLImbruvica+Venclexta R/R MCLImbruvica R/R FL/MZLVenclexta Higher Risk MDS(for AA on Ph1 data)Epcoritamab 3L R/R DLBCL(for AA on Ph2 data)Vraylar Ph3 aMDDABBV-951 Advanced PDQulipta Chronic Migraine PreventionSkyrizi UCVenclexta 3

63、L+MM w/t(11;14)Imbruvica 1L FLTeliso-V NSCLC(submit for AA on Ph2 data)Navitoclax 1L and R/R MFBoNTE(Short-Acting Toxin)Glabellar LinesBotox MasseterBotox PlatysmaBotox Episodic MigrainePh3/Registrational Data ReadoutsRinvoq Ph3 CD Induction/MaintenanceVenclexta Ph3 3L+MM t(11;14)(CANOVA)Imbruvica+V

64、enclexta Ph3 R/R MCL(SYMPATICO)Imbruvica Ph3 R/R FL/MZL(SELENE)Venclexta Ph1/2 Higher Risk MDSEpcoritamab Ph2 3L R/R DLBCLNavitoclax Ph2 R/R MFQulipta Ph3 Chronic Migraine PreventionSkyrizi Ph3 UC Induction/MaintenanceRinvoq Ph3 GCAImbruvica Ph3 1L FLTeliso-V Ph2 NSCLCEpcoritamab Ph3 3L DLBCLNavitoc

65、lax Ph3 1L MFBoNTE(Short-Acting Toxin)Ph3 Glabellar LinesBotox Ph3 MasseterBotox Ph3 PlatysmaBotox Ph3 Episodic MigraineEarly-Stage POCData ReadoutsCystic Fibrosis Triple Combo(C1/C2/P)Ph2ABBV-154(TNF-Steroid ADC)Ph2 RAABBV-599(JAK/BTK)Ph2 SLEABBV-647(PTK7 ADC)Ph1 NSCLCABBV-011(SEZ6 ADC)Ph1 SCLCABBV

66、-151(GARP/TGFb1)Ph1 Solid Tumors*TTX-030(CD39)Ph1 Solid TumorsAGN-151607(SNARE)Ph2 Atrial FibrillationAGN-231868(Chemokine)Ph2 Dry EyeAGN-242428(RORg)Ph2 Dry EyeABBV-154(TNF-Steroid ADC)Ph2 CD InductionABBV-154(TNF-Steroid ADC)Ph2 PMRABBV-GMAB-3009(CD37)Ph1 Heme TumorsABBV-CLS-579/484(PTPN2)Ph1 Soli

67、d TumorsABBV-155(BCL-xL ADC)Ph1 Solid Tumors*Eftoza(Trail)Ph1 Solid/Heme Tumors*Elezanumab(RGMa)Ph2 Spinal Cord InjuryElezanumab(RGMa)Ph2 StrokeAGN-241622(Alpha2)PresbyopiaAs of January 11,2022AA=Accelerated Approval*Early Oncology programs where monotherapy results did not warrant advancement;asset

68、s will continue to be evaluated in combination studies.J.P.Morgan Healthcare Conference|January 11,202218Not for promotional usePortfolio of leading brands in attractive and sustainable marketsPipeline of innovative,highly differentiated assets to address significant unmet needs,with potential to dr

69、ive significant growthCompelling capital allocation philosophy balanced between supporting growth and returning capital to shareholdersTrack record of strong execution,consistently meeting or exceeding financial commitments to deliver industry leading financial performanceA unique investment vehicle

70、,offering top-tier revenue and EPS growth,significant cash flow and strong return of capital to shareholdersAbbVie:A Unique Investment Opportunity Poised for Continued Strong Shareholder ReturnsJ.P.Morgan Healthcare Conference|January 11,202220GAAP to Non-GAAP Reconciliations2001620172018

71、201920202021EAs reported(GAAP)$2.56$1.10$3.13$3.63$3.30$3.66$5.28$2.72$6.31 Adjusted for specified items:Acquisition related costs0.230.180.450.680.931.003.238.115.22Separation costs0.100.240.13-Acquired in-process R&D,milestones and other R&D expenses0.210.170.350.170.290.360.450.850.75Calico colla

72、boration-0.46-0.32-0.28Stemcentrx-related impairment-2.660.56-Shire termination-1.120.10-U.S.tax reform repatriation tax-2.81-Other impacts related to tax law change-0.12(2.04)(0.40)-(1.02)-Other0.040.050.130.220.310.31(0.58)(0.10)0.09As adjusted(non-GAAP)$3.14$3.32$4.29$4.82$5.60$7.91$8.94$10.56$12

73、.65 Acquisition related costs primarily include intangible asset amortization,changes in the fair value of contingent consideration,and transaction,financing,and integration costs associated with acquisitions as well as amortization of acquisition date fair value step-up for inventory.Separation cos

74、ts are expenses related to the separation of AbbVie from Abbott.Acquired in-process R&D,milestones and other R&D expenses primarily consist of upfront and milestone payments associated with R&D collaborations and licensing arrangements.Other primarily includes charges and resolutions of litigation m

75、atters,restructuring charges associated with streamlining global operations,tax audit settlements,charitable contributions,COVID-19 related expenses and the Reata divestiture.Diluted earnings per shareNet revenuesAdjusted net revenues exclude other revenue of$81 million in 2014,$40 million in 2015,$

76、78 million in 2016,$20 million in 2018,$20 million in 2020,and$75 million in 2021.Other revenue primarily represents collaboration milestone revenue and prior period royalty revenue.Note:Based on company guidance as of October 29,2021.Stated as mid-point of the estimated range of$6.29 to$6.33(GAAP d

77、iluted EPS)and$12.63 to$12.67(adjusted EPS,non-GAAP).J.P.Morgan Healthcare Conference|January 11,202221AbbVies Partnered AssetsImbruvica jointly developed with Janssen BiotechVenclexta jointly developed with RocheSkyrizi developed in cooperation with Boehringer IngelheimVraylar developed in cooperat

78、ion with Gedeon RichterABBV-0805 developed in cooperation with BioArcticCCW702 developed by Scripps in a first-in-patient trial and AbbVie holds option for additional developmentCLBR001/SWI019 developed by Calibr in a first-in-patient trial and AbbVie holds option for additional developmentAL002/AL0

79、03 developed by Alector through Phase 2 and AbbVie holds option for additional developmentTTX-030 developed by Trishula Therapeutics through Phase 1b and AbbVie has option to lead global developmentABBV-2029 developed by CytomX Therapeutics through clinical proof of concept and AbbVie holds option f

80、or additional developmentABBV-647 developed in cooperation with PfizerEpcoritamab/GEN3009 developed in partnership with GenmabJAB-3068/3312 developed in partnership with JacobioHPN-217 developed by Harpoon through Phase 1/2 and AbbVie holds option for additional developmentRGX-314 co-developed by RE

81、GENXBIO and AbbVieABBV-IMAB-TJC4 co-developed by I-Mab and AbbVieABBV-CLS-579/484/7262 co-developed by Calico and AbbVieAcazicolcept(ALPN-101)developed by Alpine Immune Sciences through current Phase 2 study and AbbVie holds option for additional developmentAztreonam/Avibactam co-developed by Pfizer and AbbVieTeliso-V licensed from Seagen and Pierre Fabre